HR Execs on the Move

Grand Rapids Ophthalmology

www.seeitclear.com

 
Grand Rapids Ophthalmology is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.seeitclear.com
  • 750 E Beltline Ave NE Ste 201
    Grand Rapids, MI USA 49525
  • Phone: 616.949.2600

Executives

Name Title Contact Details

Similar Companies

Cardiovascular Services of America

Cardiovascular Services of America is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Medical and Surgical Clinic of Irving

Medical and Surgical Clinic of Irving is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Asuragen

"Asuragen has its roots in Ambion, ""The RNA Company."" Ambion is a molecular biology reagent company with a strong focus on RNA. Asuragen is the successor entity to Ambion. Ambion was formed in 1989 by Matt Winkler, then a University of Texas professor"

WDBR

WDBR is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Gritstone Oncology

Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.